Govt Invites Proposals Under Rs 50 Billion Pharma-MedTech Scheme

03 Oct 2025 CW Team

Revised guidelines have been issued to enhance the scheme’s effectiveness. For early-stage projects, MSMEs and startups may seek support of up to Rs 50 million for projects costing up to Rs 900 million. For later-stage projects, companies, MSMEs and startups may apply for assistance up to Rs 10 billion for projects valued at Rs 28.5 billion. Early-stage projects will receive 100 per cent support up to Rs 10 million, and 50 per cent beyond that, capped at Rs 50 million. Later-stage projects will receive 35 per cent support, capped at Rs 10 billion.

In Strategic Priority Innovation (SPI) areas—such as rare diseases, antimicrobial resistance, vaccine-preventable illnesses, tropical vector-borne diseases and pandemic pathogens—later-stage projects may receive 50 per cent assistance, capped at Rs 10 billion.

The scheme also incentivises industry, MSMEs and startups to collaborate with leading academic and government research institutions, offering preferential selection for up to nine early- and late-stage projects involving significant partnerships. Assistance may also be used for in-licensing research outputs from such institutions, linking academic strengths with industry’s capacity to scale technologies to market.

Institutional enablers will be strengthened through Centres of Excellence at seven NIPERs, acting as advanced research hubs. The NIPER Academia-Industry Coordination Committee will further enhance collaboration, while a digital Pharma-MedTech Innovation Exchange will connect innovators with investors, mentors and global opportunities.

The fully digital application process opened on 1 October 2025 via the PRIP portal. By attracting both domestic and international participation, the scheme aims to accelerate affordable, high-quality healthcare solutions, strengthen India’s public health resilience and position the country as a global leader in pharmaceutical and MedTech innovation.

The Department of Pharmaceuticals has opened applications for research and innovation projects under its Promotion of Research and Innovation in Pharma-MedTech Sector (PRIP) scheme, a landmark initiative aimed at transforming India into a globally competitive, innovation-led hub. With an approved outlay of Rs 50 billion, the scheme is expected to support around 300 projects, catalysing total R&D investment of about Rs 110 billion in new medicines, complex generics, biosimilars and novel medical devices.Revised guidelines have been issued to enhance the scheme’s effectiveness. For early-stage projects, MSMEs and startups may seek support of up to Rs 50 million for projects costing up to Rs 900 million. For later-stage projects, companies, MSMEs and startups may apply for assistance up to Rs 10 billion for projects valued at Rs 28.5 billion. Early-stage projects will receive 100 per cent support up to Rs 10 million, and 50 per cent beyond that, capped at Rs 50 million. Later-stage projects will receive 35 per cent support, capped at Rs 10 billion.In Strategic Priority Innovation (SPI) areas—such as rare diseases, antimicrobial resistance, vaccine-preventable illnesses, tropical vector-borne diseases and pandemic pathogens—later-stage projects may receive 50 per cent assistance, capped at Rs 10 billion.The scheme also incentivises industry, MSMEs and startups to collaborate with leading academic and government research institutions, offering preferential selection for up to nine early- and late-stage projects involving significant partnerships. Assistance may also be used for in-licensing research outputs from such institutions, linking academic strengths with industry’s capacity to scale technologies to market.Institutional enablers will be strengthened through Centres of Excellence at seven NIPERs, acting as advanced research hubs. The NIPER Academia-Industry Coordination Committee will further enhance collaboration, while a digital Pharma-MedTech Innovation Exchange will connect innovators with investors, mentors and global opportunities.The fully digital application process opened on 1 October 2025 via the PRIP portal. By attracting both domestic and international participation, the scheme aims to accelerate affordable, high-quality healthcare solutions, strengthen India’s public health resilience and position the country as a global leader in pharmaceutical and MedTech innovation.

Equipment

29 Nov 2025

Powering India’s Infra Future

Excon 2025, South Asia’s largest construction equipment exhibition, is set to return in a grand 13th edition from 9-13 December 2025 at the Bangalore International Exhibition Centre (BIEC), Bengaluru. Organised by the Confederation of Indian Industry (CII) and supported by the Indian Construction Equipment Manufacturers’ Association (ICEMA), the mega event is expected to reinforce its position as the premier marketplace for construction technologies, equipment and infrastructure solutions. The event will host over 1,250 exhibitors, including 160+ international participants, and attract mor..

Infrastructure Urban

29 Nov 2025

India will be a strategic part of our growth to 2028

Smiley Monroe is strengthening its footprint in India as a key growth market for its conveyor belts and engineered components business. In this interaction, Prabhu Gopinath, Operations Director, outlines the company’s expansion roadmap, quality focus, and sustainability commitments driving future scale.Can you share Smiley Monroe's journey and its core mission?Smiley Monroe was started in Northern Ireland in 1979, supplying conveyor belts to local quarries. Since then, the company has grown to become a global leader in the supply of endless belts and CNC-cut rubber and plastic part..

Equipment

29 Nov 2025

Infra Engineers India Pvt Ltd Accelerates Hybrid Excavation

Infra Engineers India Pvt Ltd (IEPL), headquartered in Chennai, has emerged as a trusted name in the used construction equipment business for nearly a decade. What sets IEPL apart is its commitment to research and development, consistently pushing the boundaries of innovation to deliver cutting-edge solutions to the industry.A first-of-its-kind hybrid excavatorAmong IEPL’s most significant achievements is the development of the pioneering Dual Electric & Diesel Hybrid Excavator—the first of its kind in the construction equipment industry, a breakthrough that even major OEMs have yet to..